Viridian Therapeutics
VRDN
212 hedge funds and large institutions have $2.5B invested in Viridian Therapeutics in 2026 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 95 increasing their positions, 50 reducing their positions, and 55 closing their positions.
390% more call options, than puts
Call options by funds: $8.23M | Put options by funds: $1.68M
90% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 50
21.93% more ownership
Funds ownership: 109.95% → 131.88% (+22%)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
13% more capital invested
Capital invested by funds: $2.21B → $2.5B (+$286M)
6% less funds holding
Funds holding: 225 → 212 (-13)
16% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 55
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$66.3M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$57.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$35.4M |
| 5 |
CP
Caligan Partners
New York
|
+$35.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$36.7M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$18.1M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$16.7M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$12.7M |
VRDN Hedge Fund Activity: Q2 2026 in Review
212 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2026, worth a combined $2.5B — up 13% from $2.21B a quarter earlier.
Sellers outnumbered buyers: 55 funds closed out of VRDN and 46 opened new positions — a net loss of 9 holders — while 50 trimmed existing stakes and 95 added.
The largest buyer was Kynam Capital Management, adding an estimated $66.3M. The largest seller was Citadel Advisors, cutting an estimated $36.7M.
- 212 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2026, down from 225 in Q1 2026.
- Funds reported $2.5B of Viridian Therapeutics stock for Q2 2026, up 13% quarter-over-quarter.
- 46 funds opened new Viridian Therapeutics positions in Q2 2026 and 55 closed out, a net change of -9 holders.
- The largest Viridian Therapeutics buyer in Q2 2026 was Kynam Capital Management, an estimated $66.3M added.
- The largest Viridian Therapeutics seller in Q2 2026 was Citadel Advisors, an estimated $36.7M sold.
Based on aggregated 13F filings for Q2 2026.